Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Week's Featured Article
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson. Article Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in the final trading days of March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A closer look at Abbott Laboratories’ situation reveals a potential disconnect between market sentiment and operational reality, and prompts a key question: Is the market’s pessimism justified, or has a meaningful value opportunity opened up for long-term investors? Separating the Signal From the NoiseAbbott's recent decline can be traced to two distinct pressures. The first is an internal headwind in its Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, mainly from market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has acknowledged the problem and laid out a clear turnaround plan. CEO Robert B. Ford outlined price and promotion initiatives and expects at least eight new product launches in 2026 to reignite volume growth, forecasting a return to growth in the second half of the year. The second factor is broader and external: a rotation of capital across the market. In periods of economic optimism, investors often shift funds away from stable, defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector in search of faster returns. That trend has pressured many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition business works through a near-term recovery, Abbott Laboratories' core remains robust, led by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model helps offset the isolated weakness in Nutrition, and the company's strongest growth signals are coming from its high-performing areas.
Medical Devices: The Medical Devices unit is firing on multiple cylinders, driven by market-leading innovation in several critical-care categories. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a growth phenomenon. The product line, which lets users track glucose without routine fingersticks, generated over $7.5 billion in sales in 2025 and continues to be a primary driver of Abbott’s success. Cardiovascular Leadership: Abbott is a major player in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, and its Structural Heart business posted strong organic growth of 8.7%. This strength stems from a portfolio of best-in-class, minimally invasive products—such as TriClip—and an active innovation pipeline, including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also positioning for future growth via the acquisition of Exact Sciences, a leader in cancer screening and diagnostics best known for its non-invasive colon cancer test, Cologuard. The deal would immediately expand Abbott’s presence in the rapidly growing, multi-billion-dollar cancer diagnostics market and add a new, high-growth vertical that could contribute meaningfully to revenue for years to come. This positive outlook is echoed on Wall Street. Analysts maintain a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying potential upside of more than 30% from current levels and suggesting many analysts view the stock as undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on dependable income, Abbott’s dividend is a standout feature. Abbott Laboratories is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record reflects a long-term commitment to returning capital to shareholders through varying market cycles. The recent pullback in Abbott’s stock price has a direct benefit for new investors: a higher dividend yield. At current levels, Abbott offers a dividend yield of about 2.5%, allowing investors to lock in a higher income rate from a historically reliable payer. The dividend also appears secure: Abbott’s payout ratio is roughly 68% of earnings and represents about 37% of cash flow, indicating the company generates ample cash to cover dividends with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott Laboratories seems out of step with its underlying business. Temporary headwinds in a single division, combined with broad market rotation, have weighed on the stock price. Yet Abbott’s fundamental growth engines are accelerating: its Medical Devices division continues to deliver strong results, the dividend remains a dependable income source, and strategic catalysts—like the Exact Sciences acquisition—could add meaningful growth. For investors with a long-term horizon, the present valuation highlights a notable gap between share price and fundamental value, presenting an opportunity worth considering. |
